[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.213.148. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 487
Citations 0
Clinical Trials Update
June 28, 2016

Smoking Cessation Drugs Pose Little Neuropsychiatric Risk

JAMA. 2016;315(24):2656. doi:10.1001/jama.2016.7814

The smoking cessation medications varenicline and bupropion do not increase the risk of moderate-to-severe neuropsychiatric adverse events, including among smokers with stable psychiatric disorders, according to the largest trial of pharmacotherapy for smoking cessation to date (Anthenelli RM et al. Lancet. doi:10.1016/S0140-6736(16)30272-0 [published online April 22, 2016]). The trial, funded by Pfizer and GlaxoSmithKline, was requested by the US Food and Drug Administration following concerns about the neuropsychiatric safety of the. The study is also the first comparative efficacy trial of the 3 first-line smoking cessation drugs .

First Page Preview View Large
First page PDF preview
First page PDF preview
×